| Date | Case | Cited by |
|---|---|---|
| 16 Dec 2024 |
[2024] EWHC 3202 (Pat)
For an ingredient to qualify as an “active ingredient” under the supplementary protection certificate regime, it must have a pharmacological, immunological or…
|
1 |
| 19 Nov 2024 |
[2024] EWHC 2941 (Pat)
A court considering a final, rather than revisitable, interim-stage declaration must have a high degree of assurance that the declaration is correct in fact…
|
1 |
| 15 Nov 2024 |
[2024] EWHC 2911 (Pat)
The court has a broad discretion when making costs orders. Although the unsuccessful party usually pays the successful party’s costs, the court must consider…
|
1 |
| 7 Nov 2024 |
[2024] EWHC 3347 (Pat)
Permission to appeal may be refused where the proposed grounds do not disclose a realistic prospect of success. The court may assess the grounds together where…
|
|
| 7 Nov 2024 |
[2024] EWHC 2807 (Pat)
A party is not bound by every formulation advanced at an earlier patent trial. The doctrine of approbate and reprobate requires a clear and unequivocal…
|
1 |
| 29 Oct 2024 |
[2024] EWHC 3086 (Pat)
For jurisdictional purposes, a serious issue to be tried must carry some degree of conviction. The claim must be coherently pleaded and properly…
|
|
| 25 Oct 2024 |
[2024] EWHC 2672 (Pat)
Inventive step is assessed by asking the statutory question of obviousness in the light of all relevant circumstances. The court must avoid treating reasonable…
|
|
| 11 Oct 2024 |
[2024] EWHC 2567 (Pat)
A patent claim must be construed by reference to its actual language and purpose. Technical features disclosed in the specification cannot be read into a claim…
|
|
| 8 Oct 2024 |
[2024] EWHC 2538 (Pat)
For a patent claim directed to a very broad class of biological constructs, the specification must disclose the asserted technical effect and provide a…
|
|
| 8 Oct 2024 |
[2024] EWHC 2524 (Pat)
Obviousness remains the statutory question whether the claimed invention was obvious having regard to the state of the art. Structured approaches such as…
|
|
| 7 Oct 2024 |
[2024] EWHC 2523 (Pat)
For obviousness and sufficiency in biotechnology cases, the skilled team must be identified realistically. Where the technology concerns protein structure, the…
|
1 |
| 26 Sep 2024 |
[2024] EWHC 2442 (Pat)
Permission to appeal should be refused where the proposed ground has no reasonable prospect of success or raises an argument that could and should have been…
|
|
| 25 Sep 2024 |
[2024] EWHC 2443 (Pat)
The court may make issue-based costs orders by assessing whether each issue was reasonably and proportionately pursued, while recognising that a point may…
|
|
| 24 Sep 2024 |
[2024] EWHC 2445 (Pat)
At a pre-trial review, the court may permit a party to answer a late-raised issue where refusing permission would cause injustice, particularly where the issue…
|
|
| 13 Sep 2024 |
[2024] EWHC 2339 (Pat)
Confidentiality restrictions in intellectual property proceedings must balance the receiving party’s need for access against the disclosing party’s interest in…
|
|
| 12 Aug 2024 |
[2024] EWHC 2111 (Pat)
In proceedings under section 40(1) of the Patents Act 1977, an invention is not identified by a mechanical, claim-by-claim construction of the granted patent.…
|
|
| 5 Aug 2024 |
[2024] EWHC 2027 (Pat)
The court may order a preliminary issue where it will finally determine an important issue, materially reduce the scope, cost or duration of the proceedings…
|
|
| 31 Jul 2024 |
[2024] EWHC 1974 (Pat)
Patent claims are construed purposively, but limitations cannot be read into them merely because the specification’s examples use a narrower arrangement. A…
|
|
| 30 Jul 2024 |
[2024] EWHC 2138 (Pat)
A trial listing should rarely be revisited. A listing officer may take account of the availability of clients and client representatives, even though the…
|
|
| 30 Jul 2024 |
[2024] EWHC 1984 (Pat)
For anticipation of a medical-use claim, the prior art must give clear and unmistakable directions and demonstrate the claimed therapeutic effect. A treatment…
|
|
| 25 Jul 2024 |
[2024] EWHC 1918 (Pat)
Permission to amend a statement of case is discretionary. A proposed amendment must have a real prospect of success and must be coherent and properly…
|
|
| 24 Jul 2024 |
[2024] EWHC 1922 (Pat)
Applications for expedition of a FRAND trial are determined by balancing the need for early resolution against fair trial preparation, the administration of…
|
1 |
| 24 Jul 2024 |
[2024] EWHC 1921 (Pat)
At the interlocutory stage, a case survives only if it has a real, rather than fanciful, prospect of success, supported by a coherent pleading and evidence. An…
|
6 |
| 10 Jul 2024 |
[2024] EWHC 1913 (Pat)
On withdrawal of an amendment application after a contested hearing, the successful respondents will ordinarily recover their costs in full under CPR r.44.2. A…
|
|
| 5 Jul 2024 |
[2024] EWHC 1733 (Pat)
A FRAND undertaking under clause 6.1 of the ETSI IPR Policy does not itself impose an immediate obligation to grant an interim licence. It requires a SEP…
|
3 |
| 2 Jul 2024 |
[2024] EWHC 1695 (Pat)
For added matter and novelty, the decisive question is whether the claimed subject matter is directly and unambiguously disclosed. A document is not a…
|
5 |
| 2 Jul 2024 |
[2024] EWHC 1648 (Pat)
For the purposes of Patents Act 1977, consent to acts that would otherwise infringe a patent may be given informally and need not be contractual. A patentee’s…
|
|
| 28 Jun 2024 |
[2024] EWHC 1664 (Pat)
In assessing obviousness, the court must consider the notional skilled team, its common general knowledge and the teaching of each item of prior art without…
|
|
| 21 Jun 2024 |
[2024] EWHC 1734 (Pat)
The sequencing of technical and FRAND trials is ordinarily a matter of case-management discretion, not a legal rule requiring validity, essentiality and…
|
3 |
| 20 Jun 2024 |
[2024] EWHC 1539 (Pat)
In patent proceedings, permission to rely on experiments should be granted where the experiments are relevant and proportionate. Experiments may provide useful…
|
|
| 13 Jun 2024 |
[2024] EWHC 1549 (Pat)
Where a validity challenge to an EU registered design was finally determined by the EUIPO in proceedings connected with pending UK infringement proceedings…
|
|
| 7 Jun 2024 |
[2024] EWHC 1408 (Pat)
Where the applicable patent-law test is unclear or developing, pleadings need not define the legal standard with absolute precision. They must identify the…
|
|
| 6 Jun 2024 |
[2024] EWHC 1407 (Pat)
An application to expedite a patent trial requires an objectively ascertainable degree of urgency before the other factors are considered. Once that threshold…
|
|
| 29 Apr 2024 |
[2024] EWHC 1066 (Pat)
An expedited patent trial requires real, objectively viewed urgency. Commercial certainty may justify expedition where a genuine and material risk remains…
|
|
| 25 Apr 2024 |
[2024] EWHC 1036 (Pat)
For service out of the jurisdiction and amendment applications, a claim must have a real, rather than fanciful, prospect of success. The pleading is assessed…
|
5 |
| 23 Apr 2024 |
[2024] EWHC 898 (Pat)
For obviousness, the skilled person is identified by the established field in which the patent’s problem arises. In nucleic-acid detection, that field may…
|
1 |
| 12 Apr 2024 |
[2024] EWHC 796 (Pat)
For inventive step, the question is whether the skilled team would have pursued the claimed clinical trial with a reasonable expectation of success. In a…
|
|
| 27 Mar 2024 |
[2024] EWHC 742 (Pat)
Retrospective permission to use documents disclosed in earlier proceedings is exceptional. The applicant bears the burden of showing special circumstances and…
|
|
| 27 Mar 2024 |
[2024] EWHC 711 (Pat)
On an application for an interim injunction, the court applies the American Cyanamid principles by assessing the adequacy of damages and, where necessary, the…
|
3 |
| 27 Mar 2024 |
[2024] EWHC 1310 (Pat)
Expedition of a patent trial requires real, objectively viewed urgency. The court must then assess the good reason for expedition, its effect on the…
|
2 |
| 8 Mar 2024 |
[2024] EWHC 533 (Pat)
A scientific adviser educates the court on technical subject matter but does not resolve technical disputes or provide opinions on issues in contention. Expert…
|
|
| 15 Jan 2024 |
[2024] EWHC 36 (Pat)
A patent claim must be construed purposively, but general claim language should not be restricted by importing limitations from a particular embodiment. A…
|